Opthea Limited is a biologics drug developer for ophthalmic diseases. The Company develops therapies for diabetic macular edema, corneal neovascularization and transplantation, and dry eye disease. Opthea serves patients and healthcare providers in Australia.

Update Opthea Participates in November Investor Conferences

Opthea to Participate in November Investor Conferences

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Opthea Ltd (OPT AU)

Update Opthea Participates in November Investor Conferences

Opthea to Participate in November Investor Conferences

Opthea Corporate Presentation - Oct 2024

Notice of Annual General Meeting/Proxy Form

Opthea Files Notice of Annual General Meeting

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)